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ABSTRACT 
Diabetes has a global prevalence in developed countries and rapidly flexing its roots in middle-and low-income countries. According to the World 
Health Organization, it is a major cause of kidney collapse, heart problems, and lower limb amputation. Diabetes mellitus is a metabolic disorder 
showing an uncontrolled increase in blood glucose levels. To date, no permanent cure has been developed for the complete restoration of impaired 
glucose haemostasis. With the use of therapeutic agents and nontherapeutic agents, glucose levels can be kept in control for a very long time. The 
foremost goal of all current ongoing treatments is to control high blood glucose levels, reduction in elevated lipid levels, and delay in the 
progression of diabetes-related complications. Various therapeutics agents are developed in recent decades, which shown very promising results in 
the management of diabetes mellitus. These agents prescribed after reviewing the clinical symptoms and situation of an individual patient. This 
review compiles noteworthy information related to clinically approved medicaments for diabetes mellitus. Review emphasis on categorization, 
mechanism of action, noted adverse effects along with the physiological responses of used medicines to treat diabetes mellitus.  
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INTRODUCTION 
Management of diabetes mellitus  
The aim of therapy in the treatment of diabetes is to control elevated 
levels of glucose levels, symptoms related to hyperglycemia, and 
chronic complications. Management of diabetes has been broadly 
classified into three domains viz., glycemic control, treat associated 
conditions, and diabetic complications [1]. Diabetes mellitus is a 
chronic condition with higher levels of glucose in the body. This 
alteration in glucose homeostasis is due to the dysfunction of insulin 
hormone, which helps in mobilization of glucose into cells and 
produce energy. Diabetes mellitus is further classified into two types 
i.e. type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus 
(T1DM) [2]. The glycated haemoglobin (HbA1c) is considered to be 
the most precise and best standard for judgment of patient diabetes 
records in recent years because it provides a sign of a 2 to 3-month 
glycaemia record [3]. Formulated insulin is obtained from different 
species of animals with little variation from human insulin e. g., 
porcine and beef insulin has been used in the treatment of severe 
diabetic conditions [4]. Porcine insulin at the C-terminal amino acid 
of chain B has alanine and human insulin contain threonine. Beef 
insulin differs with three different substitutions viz., alanine (B30), 
valine (A10), and alanine (A8) [5, 6]. These isolated forms of insulin 
were used when DNA recombinant technology is not available. They 
are usually avoided due to adverse immunological responses like 
type I allergy and injection-site lipoatrophy [7, 8]. American diabetes 
association has laid down four criteria for the diagnosis of diabetes. 
1. Fasting glucose level ≥ 126 mg/dl (impaired glucose tolerance) 
and non-fasting plasma glucose ≥ 200 mg/dl 
2. Oral glucose tolerance test (OGTT) ≥ 200 mg/dl 
3. Hyperglycaemic symptoms (Polyphagia, polyuria, polydipsia) 
4. Glycated haemoglobin (HbA1c) ≥ 6.5 %  
The Management of diabetes mellitus is followed by insulin therapy, 
oral hypoglycaemic drugs, other chemical agents, and non-
therapeutic methods [9]. The present review includes particulars of 
currently used allopathic medicaments in the treatment of diabetes 
mellitus worldwide. The main objective to compile the present 
review systematically to learn and narrate with classifications, 
mechanisms of actions, efficacy, and common side effects of FDA 
approved drugs used in antidiabetic therapies as monotherapy, add-
on therapy, or in combinations. This review also prominence on 
physiological reactions like effects on insulin resistance and insulin 
sensitivity, weight gain or loss, developmental risk, or decline in risk 
for diabetic complications produce by antidiabetic drugs. It also 
vaguely covers the effects of hypoglycaemic drugs on metabolic 
activities and elevated biochemical levels, which are commonly 
reported in diabetes mellitus patients. The major databases like 
Google Scholar, MEDLINE, Scopus-Elsevier, Directory of Open Access 
Journal (DOAJ), and Open J-Gate are employed to compile the 
current review in January 2020. The important keywords such as 
antidiabetic drugs, hypoglycaemic drugs, T1DM and T2DM drugs, 
oral hypoglycaemic medicaments, types of insulin, and mechanism 
of action of antidiabetic drugs are brought into play for literature 
compilation.  
Insulin therapy  
Insulin therapy is the main course of treatment for T1DM and 
uncontrolled hyperglycaemia T2DM [1]. The various insulin delivery 
systems are available for the administration of insulin e. g., portable 
pen injectors, inhaled insulin, insulin degludec, insulin syringes, and 
infusion pumps. Insulin is also administered intravenously, 
intramuscular, and traditionally insulin is administered by a 
subcutaneous route [10]. Insulin therapy is given to control abrupt 
glucose changes in the diabetic state. Thus, insulin administered 
must be similar in pharmacokinetic profile as that of endogenous 
insulin released from the pancreas, i.e., a rapid rise in blood 
concentration, short duration of action and rapid clearance [11]. 
Commercial available insulin preparations are different from human 
insulin in the amino acid sequences, solubility, and onset/duration 
of action. Four types of injectable insulin preparations are available 
with the different onset of actions and prepared with recombinant 
DNA technology viz., rapid-acting, short-acting, intermediate-acting, 
and long-acting [12]. Nearly, all the long-acting insulin reduces the 
levels of glycated haemoglobin (HbA1c) levels to normal limits [13]. 
Type 1 diabetic patients are treated with insulin therapy after 
confirmation of disease symptoms. Patients counseling is necessary 
before prescribing insulin therapy, e. g., amount of food intake in 
terms of carbohydrate, need for physical activity, and hypoglycaemia 
effects [14]. Two types of insulin therapy regimens are followed in 
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the management of diabetes i.e. intensive and conventional therapy. 
Intensive insulin therapy is also known as flexible insulin therapy, in 
which current glucose levels and amount of carbohydrate intake in 
the meal is considered before the administration of human regular 
insulin [15]. Hypoglycaemia is the most common reported side effect 
in intensive insulin therapy [16]. In conventional insulin therapy, 
premixed human insulin (30% regular and 70 % NPH) is 
administered before breakfast and dinner, which is followed by fixed 
diet plans [17]. The intensive insulin therapy consisted of daily three 
or more insulin injections and conventional insulin therapy is 
designed to control glucose levels with one or two insulin injections 
daily [18]. Intensive insulin therapy delays diabetic complications 
related to T1DM, e. g., nephropathy, neuropathy, retinopathy, and 
microvascular complications when compared with conventional 
insulin therapy [19]. Diabetic patients, along with complications like 
coronary artery surgery, acute stroke, stress, and acute myocardial 
infarction, have a 20% higher risk of death. Intensive insulin therapy 
in diabetic and non-diabetic patients with critical illnesses or the surgical 
intensive care unit reduces morbidity and mortality [20]. In the case of 
childhood diabetes especially in T1DM, intensive insulin therapy is found 
to be safer [21]. T2DM patients which undergo gastrectomy for cancer 
treatment, intensive insulin therapy, reduces short term morbidity [22]. 
In acute neurological injury, intensive insulin therapy shows better 
control of glucose levels and reduces morbidity [23]. The therapy causes 
severe hypoglycemia if regular monitoring of plasma glucose levels is not 
recorded. Thus, new automated techniques like islet transplantation, 
insulin delivery, and preservation of endogenous insulin have been 
developed in recent years [24]. 
Rapid-acting insulin 
A rapid-acting insulin is the safe, very fast onset of action, rapid 
clearance, and effective for a short duration. Commercially, three 
injectable forms are available viz., insulin lispro, insulin aspart, and 
insulin glulisine. A rapid-acting analog does not cause 
hypoglycaemia or nocturnal hypoglycaemia and shows better 
control of postprandial glucose [25]. These insulin analogs can be 
administered before or immediately after meals [26]. Insulin lispro 
is first marketed insulin preparation in the USA. Insulin lispro has 
alternation in the amino chain-B of insulin, i.e., proline (B-29) and 
lysine (B-28). This alteration increases the dissolution rate of insulin 
because the dimeric form of insulin is converted into monomer and 
rapidly absorbed, but this modification does not change receptor 
binding affinity [27]. Insulin aspart is another commercially 
available rapid-acting insulin preparation for human use and made 
by the substitution of proline (B-28) with aspartic acid. This 
exchange alters the interaction between monomer-monomer, i.e., 
aspartic acid (B-28) and glycine (B-23), which cause a decrease in 
insulin self-aggregation [12, 28]. Insulin glulisine causes quick 
disposal of postprandial glucose after post-meal and physiological 
action similar to regular human insulin [29]. It is produced by 
substitution of lysine in place of asparagine at B-3 and glutamic acid 
at B-29 replacing lysine [12]. Insulin glulisine in the solution form 
exists as a monomer without zinc and has rapid absorption. Thus, it 
is less immunogenic when compared with other rapid-acting insulin 
but may cause rare insulin autoimmune syndrome [30]. It is proving 
to be the most effective and safe insulin preparation for children 
suffering from T1DM [31]. 
Short-acting insulin 
Short-acting insulin analogs did not show any hazard of severe 
hypoglycaemia and shown better management of HbA1c, 
postprandial glucose, and diabetic ketoacidosis [32]. Regular insulin 
is short-acting insulin made by DNA recombinant technology. It 
exists as a hexamer form, which is bulky and creates depot upon 
subcutaneous injection and result delay in transportation through 
blood [1]. The onset of action of regular insulin is appearing within 
30 min and the duration of action is about 2 to 3 h [12]. 
Intermediate-acting insulin 
Intermediate-acting insulin has delay onset of action and absorption. 
Three types of intermediate-acting insulin have been used clinically 
viz., NPH (Neutral Protamine Hagedorn or isophane), insulin 
glargine, and insulin detemir. NPH at neutral pH is a combined 
product of insulin and stoichiometric protamine in the isophane 
ratio, i.e., neither insulin nor protamine found in large 
concentrations [33]. NPH is poorly soluble insulin product in blood 
and due to this property, it results in delayed onset of action (onset 
of action is 2-5 h and duration of action is 4-5 h). NPH insulin shows 
little improvement in HbA1c level when compared with other 
intermediate-acting insulins [12]. Insulin glargine, intermediate-
acting insulin, is having two modifications, i.e., the addition of two 
arginine molecules at C-terminus of B-chain of human insulin and 
replacement of asparagine by glycine. This addition of arginine 
causes a slight increase in the solubility of insulin glargine towards 
acidic pH and a shift in isoelectric point from pH 5.4 to 6.7 [34]. 
Insulin glargine has shown a greater affinity towards insulin-like 
growth factor-1 receptors compared to regular insulin [35]. The 
onset of action of insulin glargine is slow, with significant activity 
maintained for 11-24 h [36]. It can be administrated any time during 
a day and significantly reduces HbA1c levels and prevent 
hypoglycemic shocks during nights [37]. Insulin detemir is a new 
long-lasting analog that is created by the substitution of myristic 
acid at B-29 position and removal of threonine from the B-30 
position [38]. These modifications cause self-aggregation and 
protein binding with albumin. The duration of action of insulin 
detemir is more than 12 h and having 1-2 h onset of action [36]. 
Insulin detemir is considered to be much safer than NPH [12]. It 
shows better control on glycaemia in T1DM because it does not 
precipitate after subcutaneous administration, binds to albumin 
protein in the blood, and forms depot, which can be buffered easily if 
a change occurs in absorption parameters [39].  
Mixtures of insulin  
A mixture of insulin is a formulation created by mixing rapid and 
short-acting insulin in the same syringe before administration such 
as insulin lispro, aspart, glulisine with NPH. Other mixtures of 
insulin are NPL (Neutral protamine Lispro) and NPA (Neutral 
Protamine Aspart) [12]. Insulin preparation containing 50 % of 
short-acting insulins are termed as high-mix insulins. These 
mixtures are well-tolerated, provide efficient control over glycaemia, 
and can be administered once or twice daily [40]. The premixed 
formulation, like 70% NPH and 30% regular insulin, improves 
efficacy, accuracy and gives better control over glycaemia [41].  
Oral antidiabetic agents  
The oral antidiabetic drugs are used for the treatment of T2DM, 
which is not controlled with diet restriction and physical exercise. 
Six categories of oral antidiabetic agents have been available in the 
market viz., biguanides, sulfonylureas, meglitinides, 
thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl 
peptidase-IV (DPP-4) inhibitors, sodium-glucose cotransporter-2 
(SGLT2) inhibitors, other agents and non-therapeutic methods [12, 
42]. The first-line therapy for T2DM treatment is started with the 
most widely used oral antidiabetic drug, i.e., metformin. The second 
line of therapy involves sulfonylureas, thiazolidinediones, glucagon-
like polypeptide-1 (GLP-1) agonists, dipeptidyl peptidase-IV (DPP-4) 
inhibitors, meglitinides, and SGLT2 inhibitors [43].  
Biguanides  
Metformin, a dimethyl biguanide, is used in the treatment of T2DM 
chronically without an increase in the risk of hypoglycemia [44]. Its 
efficacy, tolerance, safety, improved peripheral insulin sensitivity 
without an increase in insulin secretion, weight gain, and other 
beneficial effects on cardiovascular systems promote this drug as 
best for the treatment of diabetes mellitus [45]. The prediabetic risk 
development in patients with impaired glucose tolerance in the 
Indian population has been significantly reduced with metformin 
[46]. American Diabetes Association and American Association of 
Clinical Endocrinologists recommend monotherapy with metformin 
for the earlier treatment of hyperglycaemia in adult T2DM patients 
[47]. Metformin is only biguanide currently in use, other derivatives 
like phenformin and buformin have been withdrawn from the 
market due to reported adverse effects like lactic acidosis and 
cardiac mortality in the early 1970s [48]. Metformin lowers blood 
glucose levels in both obese and non-obese T2DM patients and 
proves to be as effective as sulfonylurea derivatives [49]. Metformin 
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clinically reduces HbA1c level and can be used in combination with 
other oral antidiabetic drugs without gastrointestinal effects [50]. 
Other cellular mechanisms for metformin are via inactivation of 
gluconeogenesis enzymes production mediated through 5’AMP-
activated protein kinase (AMPK), increase glucose uptake in skeletal 
muscles, and adipocytes [51]. AMPK mediated mechanism of action 
of metformin has been challenged by genetic loss-of-function studies 
and suggested other AMPK-independent possible mechanisms that 
explain metabolic effects and side effects of metformin [52]. 
Metformin also acts through peroxisome proliferator-activated 
receptor (PPAR)-α, which induces islet incretin secretion and 
increases the glucagon-like peptide 1 (GLP-1) levels [53]. In skeleton 
muscles, metformin causes delocalization of GLUT1 protein but no 
effect on GLUT4 glucose transporters and stimulates glucose uptake 
[54]. Metformin has also been found to reduce cancer risk in T2DM 
[55]. Weight loss is associated with metformin in long term 
treatment. Hypoglycemia is usually not reported with metformin 
unless it is administered with sulfonylureas and insulin [56]. The 
gastrointestinal disturbances like anorexia, diarrhoea, metallic taste, 
and gut discomfort are common side effects reported with 
metformin but can be resolved with dose modifications [57].  
Sulfonylureas  
Sulfonylureas are developed in the 1920s and used in the treatment of 
T2DM. The chronic use of sulfonylurea normalizes insulin levels to 
baseline with reduced glucose levels. Sulfonylurea is a hormone-
releasing agent [58]. Sulfonylurea acts as insulin secretagogues and 
stimulates insulin release from β-cells of the pancreas [59]. 
Sulfonylureas are classified into two group’s viz., first and second-
generation agents. The less potent agents are including in first-
generation agents, e. g., Acetohexamide, Chlorpromazine, Tolazamide, 
and Tolbutamide. The potent sulfonylureas are included in second-
generation agents e. g., Glibenclamide, Glimepiride, Gliclazide, and 
Glipizide are available in the markets for the treatment of T2DM [60]. 
They inhibit ATP-sensitive K-channels in β-cell and initiate a cascade 
of events that result in the release of insulin from granules. ATP-
sensitive K-channels is a complex consisting of two subunit proteins 
Kir6.2 (pore-forming subunit) and SUR1 (drug-binding regulatory 
subunit) [61]. SUR1 is a receptor binding site for sulfonylurea, which 
initiates the closing of ATP-K+channels and decreases efflux of 
potassium, which causes depolarization of the plasma membrane of β-
cell. Cellular influx triggers depolarization and is mediated through 
voltage-dependent Ca2+-channels, and promotes the first and second 
phases of insulin secretion from preformed insulin granules [62]. 
Gliclazide and tolbutamide selectively inhibit ATP-sensitive K-
channels in β-cell through SUR1 subunit, not SUR2 subunit in cardiac 
and smooth muscle. Other agents like glibenclamide, glimepiride, 
repaglinide, and meglitinide inhibit both subunits of ATP-sensitive K-
channels [63]. Hypoglycaemia, an increase in body weight, and 
secondary failure are noted side effects of sulfonylureas [64]. The 
chronic use of sulfonylureas significantly increases the risk of 
coronary heart disease in women [65]. 
Meglitinides 
Meglitinides are nonsulfonylurea insulin secretagogues and act as 
rapid-acting postprandial insulin releasers. They too increase insulin 
secretion similar to sulfonylurea. The two marketed meglitinides are 
repaglinide and nateglinide [66]. Meglitinides bind to Kir6.2 (pore-
forming subunit) of ATP-sensitive K-channels present on the plasma 
membrane of β cells of the pancreas [67]. Meglitinides are not effective 
in patients with dysfunction β-cells in the pancreas [68]. The 
monotherapy with repaglinide proves to be more effective in reducing 
HbA1c and fasting glucose levels in comparison to nateglinide [69]. 
Repaglinide shows better tolerance and appears to be a safe 
alternative in geriatrics diabetic patients [70]. They have a rapid and 
short duration of action due to short half-life and potentiate only first-
phase insulin release. This contributes to a lower risk of 
hypoglycaemia. The adverse reactions of meglitinides are similar to 
sulfonylurea but with a mild decrease in body weight [71].  
Thiazolidinediones 
Thiazolidinediones or glitazones are a new class of oral antidiabetic 
agents and are FDA approved drugs for T2DM, e. g., pioglitazone and 
rosiglitazone. Thiazolidinediones enhance insulin action, increase 
glucose muscle uptake, and cause suppression of gluconeogenesis. 
They reduce the concentration of circulating free fatty acids, 
triglycerides, and cause a rise in the levels of HDL and LDL 
cholesterol [72]. Thiazolidinediones decrease insulin resistance by 
repression of hepatic glucose output and increasing insulin-
dependent glucose metabolism, thus, used in the treatment of T2DM 
associated with insulin resistance [73]. Thiazolidinediones enhance 
insulin sensitivity and alter transcription of genes which modulate 
carbohydrate and lipid metabolism. They are ligands for peroxisome 
proliferative activated receptor-gamma (PPAR-gamma) in muscle, 
adipose tissue, and liver [71]. PPAR-gamma activation causes 
transcription in genes for lipoprotein enzyme lipase, adipocyte fatty 
acid-binding protein, fatty acyl-CoA synthase, glucokinase, and 
GLUT4. Thiazolidinediones diminish insulin resistance through the 
activation of endocrine signalling in skeletal muscle and liver [74]. 
Rosiglitazone and other PPAR gamma activator agents inhibit 
activation of the c-Jun NH2-terminal kinase (JNK) signaling pathway 
and enhance the survival rate of β-cells of the pancreas [75]. The 
reported side effect of thiazolidinediones is oedema when used in 
combination therapy with insulin. Thiazolidinediones also aggravate 
the risk of congestive heart failure in T2DM patients [76].  
Alpha-glucosidase inhibitors (AGIs) 
Alpha-glucosidase is a membrane-bound enzyme present in the 
small intestine and assists in the absorption of carbohydrates after a 
meal [77]. Alpha-glucosidase inhibitors (AGIs) have a similar 
mechanism of action, i.e., inhibition of carbohydrates absorption 
from the gastrointestinal tract. AGIs are pseudo-sugars that 
competitively and reversibly inhibit the α-glucosidase enzyme and 
cause a delay in the absorption of carbohydrates from the gut [78]. 
These are used in the management of T2DM patients with impaired 
glucose tolerance [79]. Voglibose, Miglitol, and Acarbose are the 
most widely used AGIs for the treatment of T2DM and decrease 
postprandial plasma glucose and insulin levels [80]. AGIs are most 
beneficial for T2DM patients having higher postprandial plasma 
glucose levels and normal HbA1c. A clinical situation where glucose 
levels are not controlled with monotherapy of other oral antidiabetic 
agents, diet, and exercise, AGIs can be used as first-line of a drug in 
combination therapy [78]. Acarbose is used as add-on therapy in 
poorly controlled T2DM patients with diet sulfonylurea and 
biguanide. The starting dose of AGI is low and administered after 
meals. These inhibitors reduce glucose level about 54 mg/dl and 
HbA1c 0.9% [81]. The common side effects of AGIs are flatulence, 
gut discomfort, diarrhoea, and bloating. Hepatic injury is a rare side 
effect reported with AGIs use [82].  
Dipeptidyl peptidase 4 inhibitor or gliptins 
There are two primary incretin hormones secreted from the 
intestine after post-meal are glucagon-like peptide-1 (GLP-1) and 
gastric inhibitory polypeptide (GIP). Incretin hormones stimulate 
insulin secretion from β-cells of the pancreas and regulate glucose 
homeostasis [83]. In response to elevated glucose concentration 
after a meal, incretin hormones (GLP-1 and GIP) enhance insulin 
release from β cells, and additionally GLP-1 decreases glucagon 
production [84]. In hypoglycaemia state, GIP promotes glucagon 
counter-regulation and increases α-cells sensitivity for glucose [85]. 
Incretin hormones action is mediated through activation of 
adenylate cyclase and high level of cyclic adenosine monophosphate 
(cAMP) [86]. Incretin mimetics are a new class of drugs used in the 
treatment and management of T2DM, e. g., dipeptidyl peptidase 4 
inhibitors (DPP-4 Inhibitor) and GLP-1 receptor agonist [87]. In 
plasma, dipeptidyl peptidase-4 (DDP-4) cause’s cleavage of two NH2-
terminal amino acids of both GIP and GLP-1, thus, block the action of 
incretin hormones which results in reducing insulin level and higher 
postprandial glucose [88]. DPP-4 Inhibitor effectively decreases 
HbA1c without causing an increase in the body weight [89]. Five 
DPP-4 inhibitors are available in market viz., sitagliptin, vildagliptin, 
saxagliptin, linagliptin, and alogliptin [90].  
Sitagliptin is a selective and efficacious dipeptidyl peptidase 4 
inhibitors used for the management of T2DM and well-tolerated 
with ongoing metformin therapy [91]. Recent studies reveal 
sitagliptin monotherapy reduces both fasting and non-fasting 
glucose level along with improved functioning of β cells in T2DM 
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[92]. Sitagliptin is also found to be valuable and safe in treatment 
T1DM. It exhibits better control over glycaemia when used in 
combination with insulin therapy. The proposed mechanism of 
action of sitagliptin in type 1 diabetes mellitus mediated through 
suppression of glucagon production [90]. Vildagliptin is a new oral 
hypoglycaemic drug and acts as a selective inhibitor of the 
dipeptidyl peptidase-4 enzyme [93]. Vildagliptin causes prolonged 
inhibition of the DPP-4 enzyme and diminishes GLP-1 degradation. It 
increases insulin secretion, decreases glucagon concentration, 
inhibits gluconeogenesis, and enhances insulin sensitivity [94]. 
Vildagliptin increases insulin to glucagon ratio, which results in the 
enhancement of glucose sensitivity of α-cell and β-cell of the 
pancreas in T2DM patients. Insulin to glucagon ratio decreases in 
the hypoglycaemic state, resulting in the stimulation of hepatic 
glucose production [95]. A recent study shows that vildagliptin 
monotherapy or in combination with other antidiabetic agents is 
safe and well-tolerated but requires add-on therapy [96]. 
Vildagliptin and metformin in combination therapy efficiently lower 
blood glucose levels as compared to glimepiride-metformin 
treatment with a lower incidence of hypoglycaemia and a slight 
increase in body weight [97]. Saxagliptin is a reversible inhibitor of 
the DPP-4 enzyme, which binds covalently on catalytic active serine 
hydroxyl site and reduces degradation of incretin hormone and 
promotes insulin secretion [98]. DPP-4 enzyme inhibitors are used 
for better tolerability in the early stage of diabetes mellitus [99]. It is 
approved by the FDA in July 2009 and recommended as an add-on to 
the non-therapeutic approach in T2DM, i.e., dietary modification and 
physical exercise [100]. Saxagliptin metabolite is less potent as a 
parent drug [101]. Saxagliptin is proved to be safe both in 
monotherapy and in combination. It is also effective in lowering 
glycosylated haemoglobin, fasting plasma glucose, and non-fasting 
glucose [102]. Saxagliptin is found to be inferior to vildagliptin but 
superior to sitagliptin in controlling glucose levels [103]. Saxagliptin 
regularizes retinal capillary flow and glucose homeostasis in T2DM 
[104]. Common side effects reported in saxagliptin monotherapy are 
diarrhoea, respiratory infection, mild hypoglycaemia, and headache 
[105]. Linagliptin, a xanthine base, is a selective inhibitor of the DPP 
4 enzyme [106]. It decreases HbA1c levels in diabetes with a good 
tolerability profile in a patient with renal defects. It is well tolerated 
in obese, geriatric patients and does not require dose adjustment 
[107]. Linagliptin shows a better safety profile over sulfonylurea 
without causing an increase in body weight, stroke, and 
cardiovascular effects [108]. It enhances insulin sensitivity and 
reduces liver fat in hepatic steatosis [109]. Alogliptin is a highly 
selective noncovalent DPP-4 inhibitor and approved by the FDA in 
January 2013. It is prescribed for monotherapy or in combination 
with metformin and pioglitazone for T2DM [110]. Alogliptin is well 
tolerated and its monotherapy gives similar control over 
hyperglycaemia as other DPP-4 inhibitors without hypoglycaemia 
[111]. The combination therapy of alogliptin and pioglitazone 
improves β cell function while monotherapy of alogliptin gives 
better control of glycaemia [112]. The recent study shows that 
alogliptin prevents the progression of non-alcoholic fatty liver 
disease in T2DM patients [113]. The common side effects reported 
with alogliptin are respiratory infection, body pain, and 
nasopharyngitis [114].  
Incretin mimetic or GLP-1 receptor agonist 
Incretin mimetic or GLP-1 receptor agonists, a new generation of 
drugs that increase insulin release, inhibit glucagon secretion, and 
reduce appetite [115]. Seven incretin mimetics are available in 
market viz., Exenatide, Liraglutide, Albiglutide, Dulaglutide, 
Semaglutide, Taspoglutide and Lixisenatide. Exenatide (exenatide 
immediate-release injection, exenatide extended-release injection) 
is GLP-1 receptor agonist and the first member of incretin mimetic. 
It is approved by the FDA in 2005 as add-on therapy with metformin 
and sulfonylurea for the management of T2DM [115]. Exendin-4 is 
39 amino acid peptide hormone having biological properties similar 
to glucagon-like peptide-1 (GLP-1). Exenatide is a synthetic product 
of exendin-4. Exenatide controls glycaemia via glucagon secretion 
suppression, progressive stimulation of insulin secretion, increase in 
β cell cellular mass, and enhancement of peripheral tissue glucose 
uptake [116]. The most common side effect reported with exenatide 
is nausea [117]. Liraglutide is a long-acting GIP-1 receptor agonist 
and having 97% resemblance to human incretin hormone, i.e., GLP-1 
[118]. Liraglutide is an injectable GLP-1 analog approved by the FDA 
in February 2014 for the management of T2DM. Clinical studies 
show that liraglutide in add-on therapy with metformin and 
thiazolidinediones decreases the higher glucose level and well-
tolerated by T2DM patients [119]. Liraglutide significantly reduces 
fasting and non-fasting glucose levels with a lower incidence of 
hypoglycaemia [120]. The obese patients are at higher risk for the 
development of diabetes and cardiovascular disease. Such patients 
are advised for weight reduction. Liraglutide decreases insulin 
resistance, lowers blood pressure, and fatty acid concentration 
[121]. The obese patient with T1DM on insulin treatment, liraglutide 
is added for better control on glucose and glycated haemoglobin 
level. Liraglutide add-on therapy causes a reduction in insulin dose 
and body weight [122].  
Albiglutide is a DPP-4 enzyme resistant long-acting GIP-1 receptor 
agonist and approved in many countries for the treatment of T2DM. 
It stimulates postprandial insulin release and delays gastric 
emptying resulting in reduced food intake [123]. Albiglutide 
administered once in a week through a subcutaneous route and 
exhibits less gastrointestinal side effects compared to other incretins 
mimetic. It is the choice of agent in diabetes with renal failure [124]. 
Dulaglutide, a GLP-1 receptor agonist, administered once in a week, 
used as an adjunct to non-therapeutic methods and produced by 
recombinant DNA technology. Various clinical trial studies show 
dulaglutide monotherapy effectively control hyperglycaemia [125]. 
Dulaglutide efficiently reduce glycated haemoglobin with common 
side effect i.e. gastrointestinal discomfort [126]. Semaglutide is the 
latest approved GIP-1 receptor agonist for the treatment of T2DM by 
the US Food and Drug Administration and European Medicines 
Agency. It shows a significant decrease in glycated haemoglobin and 
systolic blood pressure along with the incidence of gastrointestinal 
side effects when administered orally once in a week [127]. 
Taspoglutide, long-acting GIP-1 receptor agonists shows better 
control over increased glycaemia compared to exenatide and 
sitagliptin. It shows adverse events like reduction in body weight 
and allergic reactions, which lead to frequent discontinuation [128]. 
Lixisenatide is a selective GLP-1 receptor agonist, used in the 
treatment of T2DM in adults. It is approved as add-on therapy to diet 
and exercise. Lixisenatide manage glycaemic record in monotherapy 
and in combination with other medicaments [129]. It acts via 
increasing glucose-induced insulin secretion with a rapid onset of 
action [130]. Lixisenatide does not produce symptomatic 
hypoglycaemia and associated cardiovascular risk [131]. 
Sodium-glucose co-transporter-2 (SGLT2) inhibitors  
SGLT2 inhibitors offer a distinctive mechanism of action and 
consider the newer class of medicament in the treatment of Diabetes 
mellitus. SGLTs are active co-transporters that facilitate passive 
glucose transporters (GLUTs) for glucose reabsorption in the 
proximal convoluted tubule. To date, six SGLTs were identified but 
SGLT1 and SGLT2 are considered valuable in glucose haemostasis 
[132]. SGLTs inhibition causes glucose excretion in urine, which 
results drop in blood glucose levels without the involvement of 
insulin. SGLT2 inhibitors such as dapagliflozin, canagliflozin, 
ertugliflozin, and empagliflozin having a low risk of hypoglycaemia 
and well-tolerated as monotherapy or in combinations other 
antidiabetic medicaments [133]. Dapagliflozin, a highly selective 
SGLT2 inhibitor, reduces blood glucose levels, glycosylated 
haemoglobin, and body weight with low-risk hypoglycaemia [134]. 
The common side effects of dapagliflozin in the clinical trial are 
female genital mycotic infections, urinary tract infections, and 
nasopharyngitis [135]. Canagliflozin is another SGLT2 inhibitor that 
effectively reduces plasma glucose levels with cardiovascular and 
renal benefits such as blood pressure and albuminuria [136]. It also 
reduces HbA1c in type 1 diabetic patients when used as an add-on to 
insulin therapy [137]. Ertugliflozin is a recent oral SGLT2 inhibitor 
that gets FDA approval as an antidiabetic drug. It prevents 
reabsorption of urine glucose and shows better control of body 
weight and blood pressure [138]. Ertugliflozin reduces 
cardiovascular risk due to a fair decline in blood pressure and body 
weight. Therefore, it is also recommended as an adjunct drug with 
non-therapeutic treatment methods like diet management and 
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exercise in T2DM [139]. Empagliflozin is a selective SGLT2 inhibitor, 
administered orally to decrease blood glucose levels via urinary 
glucose excretion. It is well tolerated and no dose adjustment is 
required in diabetic patients with renal or hepatic impairment [140]. 
Empagliflozin in a clinical trial on T2DM patients with 
cardiovascular disease show marked reduction in cardiovascular 
risk but urosepsis or genital infection was sporadic reported [141] 
Other agents  
Amylinomimetic drugs are the synthetic analogue of amylin, a 
naturally occurring 37-amino-acid peptide hormone released from 
the pancreas, and helps in glucose homeostasis. T2DM patient 
possesses a low level of amylin while T1DM patient does not 
produce amylin from the pancreas [142]. Pramlintide, an approved 
amylinomimetic drugs by the US FDA for the treatment of T1DM 
along with insulin, and in the case of T2DM, it is used as an adjunct 
with insulin, metformin and sulfonylurea [143]. Pramlintide reduces 
postprandial blood glucose in both T1DM and T2DM patients with 
side effects like hypoglycaemia [144]. Bromocriptine mesylate, 
dopamine (D2) agonist approved by the FDA for the treatment of 
T2DM and used as both monotherapy and in combination with other 
oral hypoglycaemic agents. Bromocriptine reset the tone of 
dopaminergic and circadian neuronal activities in the hypothalamus 
and central nervous system [145]. The drug is well-tolerated, 
reduces glycated hemoglobin by 0.4–0.8%, and reduce 
cardiovascular risk [146].  
Non-therapeutic methods 
In recent decades, the incidence of diabetes is constantly increasing 
and widely spread among Indian communities especially in males 
[147, 148]. The higher prevalence of obesity and diabetes in the 
urban population is related to unhealthy lifestyles, i.e., lack of 
exercise, unhealthy dietary habits, and overeating [149, 150]. 
Diabetes mellitus even in early on stages cause a decline in skeletal 
muscle strength and loss of physical function [151]. Diet control and 
weight reduction have shown an advantageous effect on insulin 
action and sugar level in the mild T2DM. It is related in terms of 
change in macronutrients and abdominal fat [152]. In T1DM, 
variation in dose regime of rapid and short-acting insulin has been 
made according to the carbohydrate content of meal to meal for 
better control on hyperglycaemia [153]. A similar approach has been 
recommended for T2DM. In obese T2DM patients, increase 
unsaturated fat consumption in meals causes a decrease in insulin 
sensitivity and an increase in body weight. Protein metabolism is 
altered in both types of diabetes mellitus. Type 1 diabetic patients 
tend to convert amino acids into glucose. Thus, modification in 
protein content has been recommended [154]. In T2DM, protein 
metabolism does not increase glucose levels instead protein 
ingestion causes stimulation of insulin release, C-peptide and 
glucagon [155]. Day to day lifestyle, lack of physical activities has 
increased developmental risk of T2DM in young, adult, and older 
people. Exercise or burning off extra calories found to be helpful in 
the prevention and control of T2DM and weight gain [156]. The 
eight-week-long exercise regime exhibit decrease in glycosylated 
haemoglobin irrespective to body weight. It is also reported that an 
increase in the intensity of physical exercise further results in the 
improvement in glycosylated haemoglobin [157]. Physical activities 
improve insulin sensitivity and decrease elevated glucose levels in 
the body. The risk of diabetes in a pre-diabetic patient with impaired 
glucose tolerance is reduced by a higher expenditure of energy and 
weight loss [158]. It also reduces the incidence of cardiovascular 
diseases associated with T2DM [159]. The patients counseling with 
informational booklet increase compliance for treatment and cause 
a decrease in glycaemic levels [160].  
CONCLUSION 
Diabetes mellitus, chronic condition with elevated glucose levels in 
the body. Its prevalence in the world increased rapidly, especially in 
urban and suburban areas. The insulin hormone maintains normal 
homeostasis in human beings. The management of insulin levels in 
terms of its concentrations and activities is the prime focus of 
current therapies. To achieve the afore-mentioned objective various 
medicaments i.e. insulin formulation and oral hypoglycaemic agents, 
were developed, which show a higher potency rate. A range of 
insulin preparation with the different onset of action was used to 
control glucose levels e. g., rapid-acting insulin, short-acting insulin, 
intermediate-acting insulin. Oral hypoglycaemic agents are used 
when insulin is present within the body but insulin sensitivity to a 
great extent reduced. These agents include metformin, sulfonylureas 
meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor 
agonists, SGLT2 inhibitors. Metformin improves insulin response, 
sulfonylureas normalize insulin levels in the body, meglitinides 
stimulate insulin release, thiazolidinediones enhance insulin 
sensitivity, and DPP-4 inhibitors reduce glucose level without 
causing an alteration in body weight, GLP-1 receptor agonists slower 
the rate of glucose absorption from the intestine and SGLT2 
inhibitors halts glucose reabsorption in the kidney. The changes in 
lifestyle i.e. exercise and diet restrictions, also help in maintaining 




All the authors have contributed equally. 
CONFLICT OF INTERESTS 
There is no conflict of interest. 
REFERENCES 
1. Goodman LS, Gilman A. The pharmacological basis of 
therapeutics. 12th Ed. New York: Mc Graw Hill; 2011.  
2. American Diabetes Association. Diagnosis and classification of 
diabetes mellitus. Diabetes Care 2010;33:S62-9. 
3. Nyenwe E, Jerkins TW, Umpierrez GE, Kitabchi AE. 
Management of type 2 diabetes: evolving strategies for the 
treatment of patients with type diabetes. 
Metabolism 2011;60:1-23. 
4. Pickup J. Human insulin. Br Med J 1986;292:155-7.  
5. Brown H, Sanger F, Kitai R. The structure of pig and sheep 
insulin. Biochem J 1955;60:556-5.  
6. Smith LF. Amino acid sequences of insulins. Diabetes 
1972;21:457-60. 
7. De Leeuw I, Delvigne C, Bekaert J. Insulin allergy treated with 
human insulin (recombinant DNA). Diabetes Care 1982;5:168-70. 
8. Ghazavi MK, Johnston GA. Insulin allergy. Clin Dermatol 
2011;29:300-5.  
9. American Diabetes Association. Classification and diagnosis of 
diabetes. Diabetes Care 2015;38:S8-16.  
10. Yaturu S. Insulin therapies: current and future trends at dawn. 
World J Diabetes 2013;4:1-7. 
11. Novak B, Metelko Z. New trends in insulin therapy. Diabetol 
Croat 2003;32:55-63.  
12. Katzung BG, Masters SB, Trevor AJ. Basic and clinical 
pharmacology. 12th Ed. New York: Tata McGraw-Hill; 2012.  
13. Monami M, Marchionni N, Mannucci E. Long-acting insulin 
analogues vs NPH human insulin in type 1 diabetes, a meta-
analysis. Diabetes Obes Metab 2009;11:372-8. 
14. McGibbon A, Richardson C, Hernandez RNC, Dornan J. 
Pharmacotherapy in type 1 diabetes. Can J Diabetes 
2013;37:S56-60.  
15. Anonymous. DAFNE study group: training in flexible, intensive 
insulin management to enable dietary freedom in people with 
type 1 diabetes: dose adjustment for normal eating (DAFNE) 
randomised controlled trial. Br Med J 2002;325:1-6.  
16. Anonymous. The diabetes control and complications trial 
research group. Adverse events and their association with 
treatment regimens in the diabetes control and complications 
trial. Diabetes Care 1995;18:1415-27.  
17. Gruesser M, Hartmann P, Schlottmann N, Joergens V. 
Structured treatment and teaching programme for type 2 
diabetic patients on conventional insulin treatment: evaluation 
of reimbursement policy. Patient Educ Couns 1996;29:123-30.  
18. Anonymous. The diabetes control and complications trial 
research group: Design and methodologic considerations for 
the feasibility phase. Diabetes 1986;35:530-45.  
Jamwal 




19. Anonymous. The diabetes control and complications trial 
research group. The effect of intensive treatment of diabetes on 
the development and progression of long-term complications 
in insulin-dependent diabetes mellitus. N Engl J Med 
1993;329:977-86.  
20. Berghe GVD, Wouters P, Weekers F, Verwaest C, Bruyninckx F, 
Schetz M, et al. Intensive insulin therapy in critically ill patients. 
N Engl J Med 2001;345:1359-67. 
21. Al-Fifi SH. Intensive insulin treatment versus conventional 
regimen for adolescents with type 1 diabetes, benefits and 
risks. Saudi Med J 2003;24:485-7. 
22. Cao SG, Ren JA, Shen B, Chen D, Zhou YB, Li JS. Intensive versus 
conventional insulin therapy in type 2 diabetes patients 
undergoing D2 gastrectomy for gastric cancer: a randomized 
controlled trial. World J Surg 2011;35:85-92.  
23. Azevedo JRAD, Lima ERM, Cossetti RJD, Azevedo RPDA. 
Intensive insulin therapy versus conventional glycemic control 
in patients with acute neurological injury: a prospective 
controlled trial. Arq Neuro Psiquiatr 2007;65:733-8. 
24. Rodger W. Insulin-dependent (type I) diabetes mellitus. Can 
Med Assoc J 1991;145:1227-37. 
25. Kitabchi AE, Gosmanov AR. Safety of rapid-acting insulin 
analogs versus regular human insulin. Am J Med 
Sci 2012;344:136-41.  
26. Joshi S, Joshi P. A review of insulin and insulin regimens in type 
2 diabetes. S Afr Fam Pract 2009;51:97-102.  
27. Noble SL, Johnston E, Walton B. Insulin lispro: a fast-acting 
insulin analo. Am Fam Physician 1998;57:279-86.  
28. Tripathi KD. Essential of medical pharmacology. 7th ed. New 
Delhi: Jaypee Brother Medical Publisher; 2013.  
29. Rave K, Klein O, Frick AD, Becker RHA. Advantage of premeal-
injected insulin glulisine compared with regular human insulin in 
subjects with type 1 diabetes. Diabetes Care 2006;29:1812-7.  
30. Ozaki N, Oiso Y. Immunologic tolerance to the insulin analogue 
glulisine. Diabetes Care 2010;33:e39.  
31. Urakami T, Kuwabara R, Habu M, Okuno M, Suzuki J, Takahashi 
S. Efficacy and safety of switching to insulin glulisine from 
other rapid-acting insulin analogs in children with type 1 
diabetes. J Diabetes Invest 2015;6:87-90.  
32. Mannucci E, Monami M, Marchionni N. Short-acting insulin 
analogues vs. regular human insulin in type 2 diabetes: a meta-
analysis. Diabetes Obes Metab 2009;11:53-9.  
33. Deckert T. Intermediate-acting insulin preparations: NPH and 
Lente. Diabetes Care 1980;3:623-6.  
34. Vajo Z, Fawcwtt J, Duckworth WC. Recombinant DNA 
technology in the treatment of diabetes: Insulin analogs. 
Endocr Rev 2001;22:706-17.  
35. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, 
Schmid C, et al. Correlations of receptor binding and metabolic 
and mitogenic potencies of insulin analogs designed for clinical 
use. Diabetes 2000;49:999-1005.  
36. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. 
Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in 
healthy men: comparison with NPH insulin and the influence of 
different subcutaneous injection sites. Diabetes Care 
2000;23:813-9.  
37. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous 
insulin infusion and multiple daily insulin injection regimen 
with glargine as basal insulin are equally better than traditional 
multiple daily insulin injection treatment. Diabetes Care 
2003;26:1321-2. 
38. Jones DR. Insulin detemir: improving the predictability of 
glycemic control. Int J Obes 2004;28:S29-34.  
39. Home P, Bartley P, Jones DR, Broutin HH, Heeg JE, Abrams P, et 
al. Insulin detemir offers improved glycemic control compared 
with NPH insulin in people with type 1 diabetes. Diabetes Care 
2004;27:1081-7.  
40. Kalra S, Farooqi MH, El-Houni AE. High-mix insulins. Indian J 
Endocrinol Metab 2015;19:686-90. 
41. Turner HE, Matthews DR. The use of fixed-mixture insulin in 
clinical practice. Eur J Clin Pharmacol 2000;56:19-25.  
42. Nathan DM. Finding new treatments for diabetes-how many, 
how fast, how good. N Engl J Med 2007;356:437-40. 
43. Stein SA, Lamos EM, Davis SN. A review of the efficacy and 
safety of oral antidiabetic drugs. Expert Opin Drug 
Saf 2013;12:153-75.  
44. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of 
metformin on cardiovascular events and mortality: a meta-
analysis of randomized clinical trials. Diabetes Obes Metab 
2011;13:221-8. 
45. Pollak M. The insulin and insulin-like growth factor receptor 
family in neoplasia: an update. Nat Rev Cancer 2012;16:159-69. 
46. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, 
Vijay V. The Indian diabetes prevention programme shows that 
lifestyle modification and metformin prevent type 2 diabetes in 
Asian Indian subjects with impaired glucose tolerance (IDPP-
1). Diabetologia 2006;49:289-97.  
47. American Diabetes Association. Summary of revisions to the 
2011 clinical practice recommendations. Diabetes Care 
2011;34:S3.  
48. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: 
from mechanisms of action to therapies. Cell 
Metab 2014;20:953-66.  
49. Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, et al. 
Long-term effect of metformin on blood glucose control in non-
obese patients with type 2 diabetes mellitus. Nutr Metab 
2010;7:1-9.  
50. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying 
the effect of metformin treatment and dose on glycemic 
control. Diabetes Care 2012;35:446-54. 
51. Viollet B, Guigas B, Sanz GN, Leclerc J, Foretz M, Andreelli F. 
Cellular and molecular mechanisms of metformin: an overview. 
Clin Sci 2012;122:253-70. 
52. Hur KY, Lee MS. New mechanisms of metformin action: 
focusing on mitochondria and the gut. J Diabetes Invest 
2015;6:600-9.  
53. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the 
incretin receptor axis via a pathway dependent on peroxisome 
proliferator-activated receptor-α in mice. Diabetologia 
2011;54:339-49. 
54. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular 
mechanism of metformin action involves glucose transporter 
translocation from an intracellular pool to the plasma 
membrane in L6 muscle cells. Endocrinology 1992;131:1165-
73.  
55. Martin Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote 
PL, Scheibye Knudsen M, et al. Metformin improves health span 
and lifespan in mice. Nat Commun 2013;4:1-9. 
56. Anonymous. The diabetes prevention program research group. 
Long-term safety, tolerability, and weight loss associated with 
metformin in the diabetes prevention program outcomes 
study. Diabetes Care 2012;35:731-7.  
57. DeFronzo RA. Pharmacologic therapy for type 2 diabetes 
mellitus. Ann Intern Med 1999;131:281-303.  
58. Gavin JR. Symposium on glyburide: summary and closing 
remarks. Am J Med 1990;89:51S-3S. 
59. Bosenberg LH, Zyl DGV. The mechanism of action of oral 
antidiabetic drugs: a review of recent literature. JEMDSA 
2008;13:80-8.  
60. Ibrahim R. Diabetes mellitus type 2: a review of oral treatment 
options. Int J Pharm Pharma Sci 2010;2:21-30.  
61. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea 
receptors and mechanism of sulfonylurea action. Exp Clin 
Endocr Diab 1996;104:1-9. 
62. Aguilar Bryan L, Nichols CG, Wechsler SW, Clement JP, Boyd AE, 
Gonzalez G, et al. Cloning the β cell high-affinity sulphonylurea 
receptor: a regulator of insulin secretion. Science 
1995;268:423-6. 
63. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. 
Sulfonylurea stimulation of insulin secretion. 
Diabetes 2002;51:S368-76.  
64. Jackson L, Robertson L. Sulphonylureas (specifically 
glibenclamide) and their correct dosage. S Afr Med J 
1989;76:286-9.  
65. Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB. Sulfonylurea use and 
incident cardiovascular disease among patients with type 2 
Jamwal 




diabetes: prospective cohort study among women. Diabetes 
Care 2014;37:3106-13.  
66. Bosenberg LH, Zyl DGV. The mechanism of action of oral 
antidiabetic drugs: a review of recent literature. J Endocr 
Metab Diab S Afr 2008;13:80-8.  
67. Gerich JE. Oral hypoglycemic agent. N Engl J Med 
1989;321:1231-45. 
68. Ambavane V, Patil R, Ainapure SS. Repaglinide, a short-acting 
insulin secretagogues for postprandial hyperglycaemia. Drug 
Rev 2002;48:246-8.  
69. Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, 
Khutoryansky N, et al. Repaglinide versus nateglinide 
monotherapy. Diabetes Care 2004;27:1265-70.  
70. Murad HAS, Hamza M, Hamza SA. Repaglinide as a safe 
alternative against hypoglycemia in fasting elderly diabetic 
patients: a single-blinded, placebo-controlled, six-period, cross-
over study. Afr J Pharm Pharmacol 2013;7:763-9.  
71. Tsang MW. The management of type 2 diabetic patients with 
hypoglycaemic agents. ISRN Endocrinol 2012:1-9. 
https://doi.org/10.5402/2012/601380 
72. Campbell I. Oral antidiabetic drugs: their properties and 
recommended use. Prescriber 2007;18:56-74.  
73. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of 
insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.  
74. Hauner H. The mode of action of thiazolidinediones. 
Diabetes/Metab Res Rev 2002;18:S10-5.  
75. Diaz Delfin J, Morales M, Caelle CH. Hypoglycemic action of 
thiazolidinediones/peroxisome proliferator-activated receptor 
γ by inhibition of the c-Jun NH2-terminal kinase pathway. 
Diabetes 2007;56:1865-71. 
76. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, 
et al. Thiazolidinedione use, fluid retention, and congestive 
heart failure. Diabetes Care 2004;27:256-63.  
77. Flanagan PR, Forstner GG. Purification of rat intestinal 
maltase/glucoamylase and its anomalous dissociation either by 
heat or by low pH. Biochem J 1978;173:553-6.  
78. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in 
clinical practice. Arch Med Sci 2012;9:899-906. 
79. Van de Laar FA. Alpha-glucosidase inhibitors in the early 
treatment of type 2 diabetes. Vasc Health Risk Manage 
2008;4:1189-95.  
80. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk 
EH, Rutten GE, Weel CV. α-glucosidase inhibitors for patients 
with type 2 diabetes. Diabetes Care 2005;28:154-63.  
81. Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus: a 
critical review of controlled trials. Diabetes Metab 
1998;24:311-20. 
82. Kao CC, Wu PC, Wu CH, Chen LK, Chen HH, Wu MS, et al. Risk of 
liver injury after α-glucosidase inhibitor therapy in advanced 
chronic kidney disease patients. Sci Rep 2016;6:1-6.  
83. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin 
hormones: similarities and differences. J Diabetes Invest 
2010;1:8-23. 
84. Holst JJ, Gromada J. Role of incretin hormones in the regulation 
of insulin secretion in diabetic and nondiabetic humans. Am J 
Physiol 2004;287:E199-206.  
85. Schweizer A, Foley JE, Kothny W, Ahren B. Clinical evidence and 
mechanistic basis for vildagliptin's effect in combination with 
insulin. Vasc Health Risk Manage 2013;9:57-64. 
86. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, 
Pederson RA. Functional expression of the rat pancreatic islet 
glucose-dependent insulinotropic polypeptide receptor: ligand 
binding and intracellular signaling properties. Endocrinology 
1995;36:4629-39.  
87. Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin 
mimetics and DPP-IV inhibitors: new paradigms for the 
treatment of type 2 diabetes. J Am Board Fam Med 
2006;19:612-20. 
88. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-
dependent insulinotropic polypeptide and truncated glucagon-
like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. 
Endocrinology 1995;136:3585-96. 
89. Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, 
Papakonstantinou E, Yovos JG. Efficacy and tolerability of 
vildagliptin as first line treatment in patients with diabetes type 2 
in an outpatient setting. J Diabetes Metab Disord 2015;14:1-7.  
90. Kutoh E. Sitagliptin is effective and safe as an add-on to insulin 
in patients with absolute insulin deficiency: a case series. J Med 
Case Rep 2011;5:1-5. 
91. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and 
safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added 
to ongoing metformin therapy in patients with type 2 diabetes 
inadequately controlled with metformin alone. Diabetes 
Care 2006;29:2638-43.  
92. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel 
C, Williams Herman DE. Effect of the dipeptidyl peptidase-4 
inhibitor sitagliptin as monotherapy on glycemic control in 
patients with type 2 diabetes. Diabetes Care 2006;29:2632-7. 
93. Ahren B, Landin Olsson M, Jansson PA, Svenson M, Holmes D, 
Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces 
glycemia, sustains insulin levels and reduces glucagon levels in 
type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84.  
94. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, 
Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 
inhibitor vildagliptin in humans. Diabetes Obes Metab 
2011;13:775-83.  
95. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes 
D, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does 
not accentuate glibenclamide-induced hypoglycemia but 
reduces glucose-induced glucagon-like peptide 1 and gastric 
inhibitory polypeptide secretion. J Clin Endocrinol Metab 
2007;92:4165-71. 
96. Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, 
Papakonstantinou E, Yovos JG. Efficacy and tolerability of 
vildagliptin as first-line treatment in patients with diabetes 
type 2 in an outpatient setting. J Diabetes Metab Disord 
2015;14:1-7. 
97. Jeon JH, Oh TK. Comparison of vildagliptin-metformin and 
glimepiride-metformin treatments in type 2 diabetic patients. 
Diabetes Metab J 2011;35:529-35. 
98. Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 
inhibitor for the treatment of type 2 diabetes mellitus. Am J 
Health Syst Pharm 2010;67:1515-25.  
99. Dave DJ. Saxagliptin: a dipeptidyl peptidase-4 inhibitor in the 
treatment of type 2 diabetes mellitus. J Pharmacol 
Pharmacother 2011;2:230-5.  
100. Hollander PA, Kushner P. Type 2 diabetes comorbidities and 
treatment challenges: rationale for DPP-4 inhibitors. Postgrad 
Med 2010;122:71-80. 
101. Anonymous. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett 
Drugs Ther 2009;51:85-6. 
102. DeFronzo RA, Hissa MN, Garber AJ, Gross JL, Duan RY, 
Ravichandran S, et al. The efficacy and safety of saxagliptin 
when added to metformin therapy in patients with 
inadequately controlled type 2 diabetes with metformin alone. 
Diabetes Care 2009;32:1649-55. 
103. Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, et al. Efficacy and 
safety of vildagliptin, saxagliptin or sitagliptin as add-on 
therapy in Chinese patients with type 2 diabetes inadequately 
controlled with dual combination of traditional oral 
hypoglycemic agents. Diabetol Metab Syndr 2014;6:1-9. 
104. Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P, et al. 
Effects of saxagliptin on early microvascular changes in 
patients with type 2 diabetes. Cardiovasc Diabetol 2014;13:1-9. 
105. Peters JU. 11 y of cyanopyrrolidines as DPP-IV inhibitors. Curr 
Top Med Chem 2007;7:579-95.  
106. Deacon CF, Holst JJ. Linagliptin. A xanthine-based dipeptidyl 
peptidase-4 inhibitor with an unusual profile for the treatment 
of type 2 diabetes. Expert Opin Invest Drugs 2010;19:133-40.  
107. Guedes EP, Hohl A, Melo TG, Lauand F. Linagliptin: 
farmacology, efficacy and safety in type 2 diabetes treatment. 
Diabetol Metab Syndr 2013;5:1-7.  
108. Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes 
patients with common renal and cardiovascular risk factors. 
Ther Adv Endocrinol Metab 2013;4:95-105.  
109. Kern M, Kloting N, Heiko G, Niessen HG, Thomas L, Stiller D, et 
al. Linagliptin improves insulin sensitivity and hepatic steatosis 
in diet-induced obesity. PLoS One 2012;7:1-10.  
Jamwal 




110. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 
inhibitors: similarities and differences. Drugs 2011;71:1441-67.  
111. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety 
of the dipeptidyl peptidase-4 inhibitor alogliptin in patients 
with type 2 diabetes and inadequate glycemic control. Diabetes 
Care 2008;31:2315-7. 
112. Raalte DHV, Genugten REV, Eliasson B, Goede DLM, Mari A, 
Tura A, et al. The effect of alogliptin and pioglitazone 
combination therapy on various aspects of β-cell function in 
patients with recent-onset type 2 diabetes. Eur J Endocrinol 
2014;170:565-74.  
113. Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H. 
Efficacy of alogliptin in preventing non-alcoholic fatty liver 
disease progression in patients with type 2 diabetes. Biomed 
Rep 2016;4:183-7. 
114. Ndefo UA, Okoli O, Erowele G. Alogliptin: a new dipeptidyl 
peptidase-4 inhibitor for the management of type 2 diabetes 
mellitus. Am J Health Syst Pharm 2014;71:103-9. 
115. Hood R, Valentine V, Mac S, Polonsky WH. Use of exenatide in 
patients with type 2 diabetes. Diabetes Spectr 2006;19:181-6. 
116. Nielsen LL, Young AA, Parkes D. Pharmacology of exenatide 
(synthetic exendin-4): a potential therapeutic for improved 
glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88. 
117. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron 
AD. Effects of Exenatide (exendin-4) on glycemic control and 
weight over 30 w in metformin-treated patients with type 2 
diabetes. Diabetes Care 2005;28:1092-100. 
118. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skoth 
TV, et al. Efficacy of Liraglutide for weight loss. Among patients 
with type 2 diabetes: the scale diabetes randomized clinical 
trial. JAMA 2015;314:687-99.  
119. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. 
Efficacy and safety of the human glucagon-like peptide-1 
analog liraglutide in combination with metformin and 
thiazolidinedione in patients with type 2 diabetes (LEAD-4 
Met+TZD). Diabetes Care 2009;32:1224-30. 
120. Garber A, Henry R, Ratner R, Garcia Hemandez PA, Rodriguez 
Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride 
monotherapy for type 2 diabetes (LEAD-3 Mono): a 
randomised, 52-week, phase III, double-blind, parallel-
treatment trial. Lancet 2008;373:473-81. 
121. Clements JN, Shealy KM. Liraglutide, an injectable option for 
the management of obesity. Ann Pharmacother 2015;49:938-
44.  
122. Kuhadiya N, Malik R, Bellini N, Patterson J, Traina A, Makdissi 
A, et al. Liraglutide as additional treatment to insulin in obese 
patients with type 1 diabetes mellitus. Endocr Pract 
2013;19:963-7. 
123. Blair HA, Keating GM. Albiglutide: a review of its use in patients 
with type 2 diabetes mellitus. Drugs 2015;75:651-63. 
124. Rendell MS. Albiglutide for the management of type 2 diabetes. 
Expert Rev Endocrinol Metab 2018;13:1-8. 
125. Burness CB, Scott LJ. Dulaglutide: a review in type 2 diabetes. 
Bio Drugs 2015;29:407-18. 
126. Wasir JS, Mithal A, Agarwal P, Mittal A. Once-weekly 
dulaglutide therapy in type 2 diabetic subjects, real-world 
evidence from a tertiary care diabetes center in India. Indian J 
Endocr Metab 2018;22:728-34. 
127. Gomez Peralta F, Abreu C. Profile of semaglutide in the 
management of type 2 diabetes: design, development, and 
place in therapy. Drug Des Dev Ther 2019;13:731-8. 
128. Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner 
R, et al. The fate of taspoglutide, a weekly GLP-1 receptor 
agonist, versus twice-daily exenatide for type 2 diabetes: the T-
emerge 2 trial. Diabetes Care 2013;36:498-504. 
129. Danial E Baker, DE Levien TL. Lixisenatide. Hosp Pharm 
2017;52:65-80. 
130. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological 
profile of lixisenatide: a new GLP-1 receptor agonist for the 
treatment of type 2 diabetes. Regul Pept 2010;164:58-64. 
131. Okere AN, Montesdeoca J, Glasper A, Diaby V. An evaluation of 
the clinical therapeutic effect of Lixisenatide in type 2 diabetes 
patients: a systematic literature review. Curr Diabetes Rev 
2018;14:363-75. 
132. Kalra S. Sodium-glucose co-transporter-2 (sglt2) inhibitors: a 
review of their basic and clinical pharmacology. Diabetes Ther 
2014;5:355-66. 
133. Nauck MA. Update on developments with SGLT2 inhibitors in 
the management of type 2 diabetes. Drug Des Dev Ther 
2014;8:1335-80. 
134. Nakajima H, Okada S, Mohri T, Kanda E, Inaba N4, Hirasawa Y, 
et al. Dapaglifozin improves treatment satisfaction in 
overweight patients with type 2 diabetes mellitus: a patient-
reported outcome study (PRO study). Diabetol Metab Syndr 
2018;10:1-11.  
135. Anderson SL. Dapagliflozin efficacy and safety: a perspective 
review. Ther Adv Drug Saf 2014;5:242-54.  
136. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review-
safety and efficacy profile in patients with T2DM. Diabetes, 
Metab Syndr Obes: Targets Ther 2019;12:209-15.  
137. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and 
safety of canagliflozin, a sodium-glucose cotransporter 2 
inhibitor, as add-on to insulin in patients with type 1 diabetes. 
Diabetes Care 2015;38:2258-65.  
138. Sharma V, Sharma S, Jaiswal S, Ghanghas RR, Boddepalli D, 
Sharma AK. Ertugliflozin: a novel anti-diabetic drug. Int J Basic 
Clin Pharmacol 2018;7:1-4. 
139. Hu J, Deng A, Zhao Y. Ertugliflozin as a monotherapy for the 
treatment of type 2 diabetes. Expert Opin Pharmacother 
2018;19:1841-7. 
140. Neumiller JJ. Empagliflozin: a new sodium-glucose 
cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 
diabetes. Drugs Context 2014;3:3-18.  
141. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, 
et al. Empagliflozin, cardiovascular outcomes, and mortality in 
type 2 diabetes. N Engl J Med 2015;373:2117-28.  
142. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: 
pharmacology, physiology and clinical potential. Pharmacol 
Rev 2015;67:564-600. 
143. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive 
therapy in treatment of type 1 and type 2 diabetes. Drug Des 
Dev Ther 2008;2:203-14.  
144. Younk LM, Mikeladze M, Davis SN. Pramlintide and the 
treatment of diabetes: a review of the data since its 
introduction. Expert Opin Pharmacother 2011;12:1439-51. 
145. DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine 
agonist for the treatment of type 2 diabetes. Diabetes Care 
2011;34:789-94. 
146. Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes 
mellitus. Indian J Endocrinol Metab 2011;15:S17-24. 
147. Kandasamy K, Rajagopal SS, Ramalingam KK, Krishnan K. 
Prevalence of diagnosed and undiagnosed diabetes in a rural 
community: a home-based screening. Asian J Pharm Clin Res 
2018;11:454-7. 
148. Kumar M, Shivgotra VK, Nanda H. Gender-wise prevalence of 
diabetes among the Indian population: a meta-analysis using R 
software. J Crit Rev 2020;7:683-91.  
149. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales 
VS, et al. Prevalence of obesity, diabetes, and obesity-related 
health risk factors 2001. JAMA 2003;289:76-9. 
150. Jain R, Jain P, Jain P. A review on treatment and prevention of 
diabetes mellitus. Int J Curr Pharm Res 2016;8:16-8.  
151. Poornima KN, Kanimozhi S, Karthick N, Saravanan A, 
Padmavathi R. Skeletal muscle: one of the silent targets of 
diabetic complications. Asian J Pharm Clin Res 2018;9:206-8.  
152. Fowle MJ. Diabetes treatment, part 1: diet and exercise. Clin 
Diabetes 2007;25:105-9.  
153. Rabasa Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. 
Effects of the meal carbohydrate content on insulin 
requirements in type 1 diabetic patients treated intensively 
with the basal-bolus (ultra lente-regular) insulin 
regimen. Diabetes Care 1999;22:667-73.  
154. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, 
et al. Nutrition principles and recommendations in diabetes. 
Diabetes Care 2004;27:S36-46. 
155. Gannon MC, Nuttall JA, Damberg G, Gupta V, Nuttall FQ. Effect 
of protein ingestion on the glucose appearance rate in people 
with type 2 diabetes. J Clin Endocrinol Metab 2001;86:1040-7.  
Jamwal 




156. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie Rosett J, Kulkarni 
K, et al. Weight management through lifestyle modification for 
the prevention and management of type 2 diabetes: rationale 
and strategies: a statement of the American diabetes 
association, the North American association for the study of 
obesity, and the American Society for clinical 
nutrition. Diabetes Care 2004;27:2067-73. 
157. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of 
exercise on glycemic control and body mass in type 2 diabetes 
mellitus: a meta-analysis of controlled clinical trials. JAMA 
2001;286:1218-27.  
158. Sigal RJ, Kenny GP, Wasserman DH, Castaneda Sceppa C, White 
RD. Physical activity/exercise and type 2 diabetes. Diabetes 
Care 2006;29:1433-8. 
159. Marwick TH, Hordern MD, Miller T, Chyun DA, Bertoni AG, 
Blumenthal RS, et al. Exercise training for type 2 diabetes 
mellitus impact on the cardiovascular risk a scientific 
statement from the American heart association. Circulation 
2009;119:3244-62. 
160. Presetiawati IIN, Andrajati R, Sauriasari R. Effectiveness of a 
medication booklet and counseling on treatment adherence in 
type 2 diabetes mellitus patients. Int J Appl Pharm 2017;9:27-31. 
 
